You are here

  • Home
  • Online First
  • Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey

Article Text

Article menu

other Versions

Download PDFPDF
Original research
Impact of COVID-19 on medical treatment patterns in gynecologic oncology: a MITO group survey
  1. Raffaella Cioffi1,
  2. Giulia Sabetta1,
  3. Emanuela Rabaiotti1,
  4. Alice Bergamini1,
  5. Luca Bocciolone1,
  6. Giorgio Candotti1,
  7. Massimo Candiani1,
  8. Giorgio Valabrega2,
  9. Giorgia Mangili1 and
  10. Sandro Pignata3
  11. on behalf of MITO group
    1. 1Obstetrics and Gynecology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
    2. 2Department of Oncology, University of Turin, Turin, Italy
    3. 3Department of Uro-Gynecological Oncology, Istituto Nazionale Tumori "Fondazione G Pascale" IRCCS, Naples, Italy
    1. Correspondence to Dr Giorgia Mangili, Obstetrics and Gynecology Department, IRCCS San Raffaele Scientific Institute, Milan, Italy; mangili.giorgia{at}hsr.it

    Abstract

    Objective COVID-19 is a global public health emergency. The increasing spread of COVID-19 presents challenges for the clinical care of patients with gynecological tumors. The Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) performed a survey to evaluate the impact of the COVID-19 pandemic on medical treatment of gynecological cancer, with a focus on chemotherapy and oral treatment with poly(ADP)-ribose polymerase inhibitors (PARP-i).

    Methods The survey consisted of a self-administered online questionnaire, sent via email between November 2020 and January 2021 to all members of MITO group.

    Results Forty-nine centers completed the questionnaire. The majority of respondents (83%) use screening tests to determine COVID-19 status in patients who were to undergo chemotherapy or oral medications. All respondents to our survey continued cancer therapy in patients who tested negative for COVID-19 during the pandemic. Seventy-three percent of respondents declared they stopped treatment with chemotherapy or PARP-i only after a positive swab and resumed therapy when negative tests were confirmed.

    Conclusions COVID-19 positivity impacted patterns of treatment in patients diagnosed with ovarian cancer within the MITO group. Further investigations are needed to evaluate whether these modifications influence oncological clinical outcomes.

    • COVID-19
    • ovarian cancer
    • medical oncology

    Data availability statement

    Data are available upon reasonable request. Deidentified participant data are stored in San Raffaele Hospital archives and can be provided upon reasonable request by contacting the corresponding author (mangili.giorgia@hsr.it).

    This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

    https://bmj.com/coronavirus/usage

    http://dx.doi.org/10.1136/ijgc-2021-002784

    Statistics from Altmetric.com

      Request Permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

      Data availability statement

      Data are available upon reasonable request. Deidentified participant data are stored in San Raffaele Hospital archives and can be provided upon reasonable request by contacting the corresponding author (mangili.giorgia@hsr.it).

      View Full Text

      Footnotes

      • Collaborators MITO Group: Daniela Sambataro (ARNAS Garibaldi-Nesima – Catania), Serafina Mammoliti (IRCSS Ospedale Policlinico San Martino – Genova), Enrico Breda (S. Giovanni Calibita Fatebenefratelli Isola Tiberina), Antonietta D’Alessio (AO San Camillo Forlanini – Roma), Giacomo Rondello (Polo Oncologico Ospedale Civico – Palermo), Valentina Arcangeli (Ospedale Infermi e Presidio di Oncologia di Rimini), Carlo Messina (Ospedale S. Chiara – Trento), Grazia Artioli (Ospedale Ca’ Foncello

        – ULSS 2 Marca Trevigiana), Francesco Maneschi (Ospedale San Giovanni Addolorata – Roma), Claudia Andreetta (Azienda Sanitaria Universitaria Integrata – Udine), Francesco Raspagliesi (Fondazione IRCCS Istituto Nazionale dei Tumori – Milano), Aida Di Stefano (Gemelli Molise Spa Hospital), Antonino Ditto (Fondazione IRCCS Istituto Nazionale dei Tumori – Milano), Isabella Maria Giovanna Garassino (Istituto Clinico Humanitas IRCCS – Rozzano), Claudia Carella (IRCCS Istituto Tumori di Bari Giovanni Paolo II), Maria Gabriella Ferrandina (Fondazione Policlinico Universitario A. Gemelli - IRCCS – Roma, Filomena Narducci (Ospedale SS. Trinità – Sora), Giovanna Cirigliano (Ospedale S. Luca – Lucca), Giacomo Corrado (Fondazione Policlinico Universitario A. Gemelli - IRCCS – Roma), Simona Borghesi (Ospedale San Donato – Arezzo), Francesco Legge (Ospedale Regionale Miulli - Acquaviva delle Fonti), Michele Bartoletti (Centro di Riferimento Oncologico (CRO), IRCCS – Aviano), Ugo De Giorgi (I.R.S.T. IRCCS, Meldola – Meldola), Anna Festi (Azienda Ospedaliera Universitaria Integrata – Verona), Graziana Ronzino (Ospedale Vito Fazzi – Lecce), Giusy Scandurra (Azienda ospedaliera per l’emergenza Cannizzaro – Catania), Anila Kardhashi (IRCCS Istituto Tumori di Bari Giovanni Paolo II – Bari), Claudio Zamagni (IRCCS Azienda Ospedaliero Universitaria di Bologna), Maria Cristina Petrella (AOU Careggi – Firenze), Anna Maria Mosconi (Ospedale Santa Maria della Misericordia – Perugia), Giancarlo Di Pinto (Ospedale Ferrari – Castrovillari), Antonella Savarese (I.N.T. di Roma Regina Elena), Alessandra Perin (Ospedale Alto Vicentino – Santorso), Teresa Di Palma (Ospedale S. Maria Goretti – Latina), Daniela Rubino (Policlinico Universitario Campus Bio Medico – Roma), Flavia Zanaboni (Fondazione IRCCS Istituto Nazionale dei Tumori – Milano), Laura Vertechy (Policlinico Umberto I Università "La Sapienza" – Roma), Marianna Roccio (IRCCS Policlinico S. Matteo – Pavia), Innocenza Palaia (Policlinico Umberto I Università "La Sapienza" – Roma), Sara Giovannoni (Policlinico Umberto I Università "La Sapienza" – Roma), Chiara Cassani (IRCCS Policlinico S. Matteo – Pavia), Domenico Sergi (I.N.T. di Roma Regina Elena), Giulia Scotto (FPO-IRCCS Candiolo – Torino), Rossella Lauria (Azienda Ospedaliera Universitaria Federico II – Napoli), Anna Myriam Perrone (IRCCS Azienda Ospedaliero Universitaria di Bologna), Saverio Danese (Azienda ospedaliera – universitaria, Città della Salute e della scienza di Torino), Giovanna Scarfone (Policlinico di Milano - Clinica Mangiagalli).

      • Contributors RC: writing – original draft, review and editing. GS: formal analysis; writing – original draft. ER, AB, LB, GC: conceptualization; data curation. MC: supervision. GV, GM, SP: conceptualization; methodology; supervision.

      • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

      • Competing interests None declared.

      • Provenance and peer review Commissioned; externally peer reviewed.